Conceptus, Inc. (NASDAQ:CPTS)

CAPS Rating: 5 out of 5

The Company develops, manufactures and markets the Essure(r) permanent birth control system, an innovative and proprietary medical device for women.


Player Avatar bigtalldaddy (< 20) Submitted: 10/27/2006 11:50:33 AM : Outperform Start Price: $19.83 CPTS Score: +26.68

i am an OB/GYN MD and with the movement of the Essure procedure into the office setting i expect to continue to see triple digit revenue growth quarter over quarter over the next 2-3 years.

Report this Post 2 Replies
Member Avatar bigtalldaddy (< 20) Submitted: 4/30/2011 9:38:39 AM
Recs: 0

Get ready for a leg up. Already missed the first $2 gain. Patient demand is increasing and docs are realizing Essure is better than Adiana. I wouldn't be surprised if they are bought (?JNJ).

Member Avatar bigtalldaddy (< 20) Submitted: 5/16/2011 9:41:47 PM
Recs: 0

Contrary to what the market thinks, this company is not dead. Give it 1 year and revenues and stock price will be up.

Featured Broker Partners